Combination therapy with peginterferon (pegIFN)-α and ribavirin (RBV) has been the standard of care (SOC) for chronic hepatitis C. Unfortunately, not all patients can achieve a sustained virologic response (SVR) with...Combination therapy with peginterferon (pegIFN)-α and ribavirin (RBV) has been the standard of care (SOC) for chronic hepatitis C. Unfortunately, not all patients can achieve a sustained virologic response (SVR) with this regimen. SVR rates are approximately 80% in patients with hepatitis C virus (HCV) genotype 2, 3, 5 and 6 and 40%-50% in patients with genotype 1 and 4. Therefore, strategies to improve SVR rates have been an important issue for clinical physicians. Several direct acting antiviral agents (DAAs) have significantly higher SVR rates when combined with pegIFN-α and RBV than pegIFN-α and RBV alone. Treatments containing DAAs have several advantages over the previous SOC, including higher specificity and efficacy, shorter treatment durations, fewer side effects, and oral administration. Based on these advantages, treatment with pegIFN-α and RBV plus telaprevir or boceprevir has become the current SOC for patients with genotype 1 HCV infection. However, many patients are either not eligible for therapy or decline treatment due to coexisting relative or absolute contraindications as well as an inability to tolerate the hematological side effects and adverse events caused by the new SOC. These factors have contributed to the advent of pegIFN-α-free regimens. The newest therapeutic regimens containing sofosbuvir and ABT-450 have shown promising results. In this review, we summarize the development of anti-HCV agents and the clinical efficacy of sofosbuvir and ABT-450-based therapies as well as the potential for future HCV studies.展开更多
Within the framework of a nonlinear chiral Lagrangian the mass spectra and the decay properties of 0^＋＋ states below 2 GeV are studied. Assuming that f0（980）, a0（980）, K0（1430）, and f0（1500） comprise an SU（...Within the framework of a nonlinear chiral Lagrangian the mass spectra and the decay properties of 0^＋＋ states below 2 GeV are studied. Assuming that f0（980）, a0（980）, K0（1430）, and f0（1500） comprise an SU（3） nonet, we make a detailed prediction about the static properties of the 0^＋＋ mesons. The substructure analysis of these states in terms of two- and four-quark components as well as a glueball component is carried out. We also consider the interaction Lagrangian and provide a preliminary study of the strong and radiative decays of the 0＋＋ mesons. The scalar glueball masses and partial widths are also presented. In view of the fact that few data of 0＋＋ mesons are clearly given in the present PDG （Particle Data Group） list and that the four-quark content of mesons is a hot issue both experimentally and theoretically, the predicted results of the paper may be helpful for upcoming experimental and theoretical studies of these mesons.展开更多
基金Supported by Grants from the National Key Basic Research Program of China, No. 2009CB522507, No. 2012CB519005Beijing Nova Program of China, No. Z12110702512071
文摘Combination therapy with peginterferon (pegIFN)-α and ribavirin (RBV) has been the standard of care (SOC) for chronic hepatitis C. Unfortunately, not all patients can achieve a sustained virologic response (SVR) with this regimen. SVR rates are approximately 80% in patients with hepatitis C virus (HCV) genotype 2, 3, 5 and 6 and 40%-50% in patients with genotype 1 and 4. Therefore, strategies to improve SVR rates have been an important issue for clinical physicians. Several direct acting antiviral agents (DAAs) have significantly higher SVR rates when combined with pegIFN-α and RBV than pegIFN-α and RBV alone. Treatments containing DAAs have several advantages over the previous SOC, including higher specificity and efficacy, shorter treatment durations, fewer side effects, and oral administration. Based on these advantages, treatment with pegIFN-α and RBV plus telaprevir or boceprevir has become the current SOC for patients with genotype 1 HCV infection. However, many patients are either not eligible for therapy or decline treatment due to coexisting relative or absolute contraindications as well as an inability to tolerate the hematological side effects and adverse events caused by the new SOC. These factors have contributed to the advent of pegIFN-α-free regimens. The newest therapeutic regimens containing sofosbuvir and ABT-450 have shown promising results. In this review, we summarize the development of anti-HCV agents and the clinical efficacy of sofosbuvir and ABT-450-based therapies as well as the potential for future HCV studies.
基金Supported by the National Natural Science Foundation of China under Grants Nos 10375039 and 90503008, the Doctoral Programme of the Education Ministry of China, and the Research Fund of the Nuclear Theory Center of HIRFL of China.
文摘Within the framework of a nonlinear chiral Lagrangian the mass spectra and the decay properties of 0^＋＋ states below 2 GeV are studied. Assuming that f0（980）, a0（980）, K0（1430）, and f0（1500） comprise an SU（3） nonet, we make a detailed prediction about the static properties of the 0^＋＋ mesons. The substructure analysis of these states in terms of two- and four-quark components as well as a glueball component is carried out. We also consider the interaction Lagrangian and provide a preliminary study of the strong and radiative decays of the 0＋＋ mesons. The scalar glueball masses and partial widths are also presented. In view of the fact that few data of 0＋＋ mesons are clearly given in the present PDG （Particle Data Group） list and that the four-quark content of mesons is a hot issue both experimentally and theoretically, the predicted results of the paper may be helpful for upcoming experimental and theoretical studies of these mesons.
